Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?Zacks Investment Research • 05/13/25
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/13/25
MindMed Reports First Quarter 2025 Financial Results and Recent Business UpdatesBusiness Wire • 05/08/25
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)Business Wire • 04/15/25
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business UpdatesBusiness Wire • 03/06/25
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025Business Wire • 02/20/25
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness Wire • 02/04/25
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety DisorderBusiness Wire • 01/30/25
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)Business Wire • 12/16/24
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 CongressBusiness Wire • 12/11/24
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)Business Wire • 12/05/24
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development StrategyBusiness Wire • 12/03/24
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance OfficerBusiness Wire • 11/18/24
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts sayProactive Investors • 11/12/24